Commonwealth Equity Services’s Gain Therapeutics GANX Stock Holding History
Bought
Maintained
Sold
Other funds holding GANX
PCM
GCP
DCM
Commonwealth Equity Services's GANX Position: Q2 2026 in Review
Commonwealth Equity Services increased its Gain Therapeutics (GANX) stake by 97% in Q2 2026, buying an estimated $53K and bringing the position to 58,456 shares worth $119K. The position accounts for ﹤0.01% of the portfolio, ranked #4229.
Commonwealth Equity Services first reported a position in GANX in Q4 2025 and has held it in 3 quarters since. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.
- Commonwealth Equity Services held 58,456 shares of Gain Therapeutics worth $119K as of Q2 2026.
- Commonwealth Equity Services bought 28,753 Gain Therapeutics shares in Q2 2026, an estimated $53K.
- Gain Therapeutics made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #4229 holding.
- Commonwealth Equity Services first reported a position in Gain Therapeutics in Q4 2025 and has held it in 3 quarters since.
- 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.
Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.